This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Stroke  • Bone Marrow Transplantation  • Hematology/ Hematologic Malignancies  • Anemias  • Hematology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Robert J. Adams, MS, MD

Arch Neurol. 2001;58:565-568.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

While the problem of stroke in the patients with sickle cell disease (SCD) has been known for more than 75 years, adequate preventive and treatment strategies are just now being tested. Recent data on prevalence and incidence have been obtained from the Cooperative Study of Sickle Cell Disease of more than 4000 patients with SCD observed in 23 US clinical centers over a 10-year period.¹ The overall age-specific incidence of first stroke in SCD (homozygous sickle cell anemia) is low (0.13%) at ages younger than 24 months, increasing to just over 1% at ages 2 to 5 years, with only a slight decrement to 0.79% at ages 6 to 9 years. The risk of brain infarction declines until a second peak is seen at ages older than 50 years, when the incidence again increases to nearly 1.3%. Although intracranial hemorrhage does occur in young children . . . [Full Text of this Article]

PATHOPHYSIOLOGY OF STROKE

TREATMENTS USED FOR STROKE

Transfusion

Hydroxyurea

Bone Marrow Transplantion (BMT)

Other Treatments

CURRENT STATE OF KNOWLEDGE

From the Department of Neurology, Medical College of Georgia, Augusta.

Corresponding author and reprints: Robert J. Adams, MS, MD, Department of Neurology, Medical College of Georgia, 1467 Harper St, HB-2060, Augusta, GA 30912.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2001;58(4):684-685.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

When Should Hydroxyurea Be Used for Children With Sickle Cell Disease?
Mueller
Pediatrics 2008;122:1365-1366.
FULL TEXT  

Sickle Cell Trait Is a Risk Factor for Early Stroke
Golomb
Arch Neurol 2005;62:1778-1779.
FULL TEXT  

Sickle Cell Trait: Innocent Until Proven Guilty
Roach
Arch Neurol 2005;62:1781-1782.
FULL TEXT  

Declining stroke rates in Californian children with sickle cell disease
Fullerton et al.
Blood 2004;104:336-339.
ABSTRACT | FULL TEXT  

Myocardial Infarction and Transient Ventricular Dysfunction in an Adolescent With Sickle Cell Disease
Deymann and Goertz
Pediatrics 2003;111:e183-187.
ABSTRACT | FULL TEXT  

Defining Thresholds for Changes in Size of Simulated T2-Hyperintense Brain Lesions on the Basis of Qualitative Comparisons
Melhem et al.
Am. J. Roentgenol. 2003;180:65-69.
ABSTRACT | FULL TEXT